The spread of COVID-19 in the Americas driven by the Omicron variant of the virus reached levels of transmission never before seen during the pandemic, with cases doubling to 6.1 million over the past week, the Pan American Health Organization (PAHO) said on January 12.
Pfizer and BioNTech Lead Globally with COVID-19 Vaccine
Argentina, Bharat Biotech, BNT162b2 (Pfizer and BioNTech), Brazil, CDC, COVID-19 booster shots, COVID-19 Vaccines, Cytokine Storm, FDA, GlaxoSmithKline, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Messenger RNA (mRNA) Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), The Wall Street Journal, Vir BiotechnologyAccording to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.
Convalescent Plasma Flunks Study in Covid-19 Patients with Severe Pneumonia
Argentina, Convalescent Plasma, COVID-19 Infections, Covid-19 Pneumonia, COVID-19 Studies, Emergency Use Authorization, FDA, Mortality, R&D, SARS-CoV-2 virus, The New England Journal of Medicine (NEJM), U.S. Health Secretary Alex AzarA study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
Plasma from recovered patients shows little benefit in those hospitalized with Covid-19: study
Antibodies, Argentina, Blood Plasma, Clinical Trials, Convalescent Plasma, Covid-19 Pneumonia, COVID-19 Studies, Donald Trump, Hospitalized COVID-19 Patients, India, New England Journal of Medicine, R&D, Researchers, Symptoms: Coronavirus Disease 2019 (COVID-19)Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.